Alnylam Pharmaceuticals
Cambridge, Mass.
Pharmaceuticals
CEO: John Maraganore, 46
Alnylam is developing a new class of medicines based on a discovery known as RNA interference (RNAi), heralded as a major scientific breakthrough. RNAi is a natural cellular mechanism that can silence specific disease-causing genes. Alnylam is teaming with major drugmakers to develop treatments for liver cancer, Huntington's disease, and other ailments.
Business Tools
A-Z Index
List & Rankings
Blogs
- Apple
- Asia
- Autos
- Branding
- Economy
- Investing
- Management Trends
- Real Estate
- Small Business
- Social Media
- Technology
